Bio-IT World May 30, 2024
A consortium of pancreatic cancer researchers sharing information in real time has shown that an oral pan-RAS inhibitor known as RMC-7977, developed by Revolution Medicines, effectively targets the common cancer-causing RAS proteins while minimally impacting normal cells—and did so across a comprehensive range of preclinical models in a series of similar experiments. Notably, the finding held when the drug was subsequently tested on separate cohorts of triple-transgenic animals run independently at two separate institutions, according to Kenneth Olive, Ph.D., associate professor of medicine at Columbia University’s Vagelos College of Physicians and Surgeons and Herbert Irving Comprehensive Cancer Center.
The published study, which appeared recently in Nature (DOI: 10.1038/s41586-024-07379-z), addresses the reproducibility question head on, he says....
Today's Sponsors
Today's Sponsor